ecog1684: Phase III Melanoma clinical trial.

In oswaldogressani/mixcurelps: Approximate Bayesian Inference in Mixture Cure Models

Phase III Melanoma clinical trial.

Description

Melanoma data from the phase III Eastern Cooperative Oncology Group (ECOG) two-arm clinical trial studied in Kirkwood et al. (1996) and obtained from the smcure package.

Usage

data(ecog1684)

Format

A data frame with 284 rows and 5 columns.

tobs

Relapse-free survival (in years).

delta

1=death or relapse, 0=censored.

TRT

Treatment: 0=control, 1=Interferon alpha-2b (IFN).

AGE

Age centered to the mean.

SEX

0=Male, 1=Female.

Source

https://CRAN.R-project.org/package=smcure

References

Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C. and Blum, R. H. (1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. Journal of clinical oncology 14(1): 7-17.

Corbiere, F. and Joly, P. (2007). A SAS macro for parametric and semiparametric mixture cure models. Computer methods and programs in Biomedicine 85(2): 173-180. https://doi.org/10.1016/j.cmpb.2006.10.008

oswaldogressani/mixcurelps documentation built on Oct. 30, 2024, 10:45 p.m.